The SMi Group will organize the second edition of the Highly Potent Active Pharmaceutical Ingredients conference of London on 21st - 22nd May 2018. BSP Pharmaceuticals S.p.A. is proud to announce Its sponsorship to this event for the first time.
The global market for Highly Potent Active Pharmaceutical Ingredients is currently on a growth fast track, largely driven by its major use in oncology for cancer treatment and more often in the form of ADCs. Over a quarter of drugs worldwide now contain HPAPIs, as they have proven to be more effective than other APIs.
However, working with APIs high in potency and cytotoxicity comes with many regulations and requirements, and presents pharmaceutical companies with challenges such as handling, containment, cost and security questions.
This conference will cover many important and in-demand aspects of the HPAPI industry, creating a networking platform for industry professionals and key players to share their knowledge and find innovative new solutions.
The core benefits to the participants of the conference will be the following four:
During this Conference, on 21st of May, Fabio Zenobi, BPS EHS & Toxicology Director, will make the presentation: “The Manufacturing of Oncological Product by a CDMO”